subject: Methods Of Antibodies Sequencing [print this page] Fusion Antibodies, a trusted CRO, delivers quick and reliable results of Antibody sequencing with unprecedented professionalism. Our pioneering services have garnered us the position of a recognized leader in Monoclonal Antibody Sequencing. From a select few revered names in the business of protein sequencing, we are one of the companies to have also sequenced dead hybridomal cells. Our unmatched strength and expansive knowledge base in this highly skilled area of research helps accelerate your discovery and validation process. For more than 8 years, we have delivered more than 500 antibody sequences for a variety of species including mouse, rat, bovine, human guinea pig, hamster, rabbits and human antibody secreting EBV cell lines. We provide for deriving a sequence from any antibody producing cell line. For any given kind of application, you can rest assured of our antibody sequencing for quality, consistency and accurate results. In addition to our services, we offer tailor-made options that meet your specific research and derivative requirements. In addition, our clients enjoy the benefits of working with an experienced biotech partner who also has the ability to tailor-make our proprietary transient expression processes to their requirements. We can perform multiple projects in parallel while maintaining our high standards of service and adhering to proposed timelinesa huge advantage to you, our clients.
For the rapid production of cell lines expressing full-length recombinant antibodies and fully humanised antibodies, Fusion Antibodies has developed advanced technology, which functions as under:
I.Murine Antibody VH and VL sequence
II.Cultured to 1mg level production for lead variant selection
III.Lead variant selected, Population undergoes MTX, Amplification steps
IV.Recombined to give 9 possible Humanised Antibody variant vectors
V.3 VH and VL variants designed
VI.Cells banked and frozen and transferred to our cGMP partners
VII.Transfected in CHO
VIII.High production clones can be selected by ELISA
During the transient expression process, the protein is expressed only over a short period of time, which is ideal for proof of concept studies since the DNA that is introduced in the transfection process is usually not integrated into the nuclear genome and will be diluted through mitosis or degraded. When the researcher has identified the target protein of interest, the production of a stable transfected cell line is the logical next step which requires the transfected gene to remain in the genome of the cells. This requires a longer timescale than the transient transfections to achieve the stable transfection. Fusion Antibodies proprietary FET (Fusion Expression Technology) is rapid and reliable. The multi-parallel screening approach utilises several proprietary vector systems for accelerating the production of recombinant protein you require. Later, Bioinformatics is applied for designing the most suitable proteins necessary for individual research projects. Be it drug development, patent application, DNA sequencing, cloning, etc. Fusion Antibodies fulfils your project requirements in a timely and cost-efficient manner. Fusion Antibodies effectively humanises murine monoclonal antibodies with the help of advanced strategies developed specifically to reduce the HAMA (Human Anti-Mouse Antibody) response in patients undergoing antibody therapy. Fusion Antibodies has worked with hundreds of biotech companies consistently delivering high quality results even on extremely challenging projects.
